NCT03201913View on ClinicalTrials.gov

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

April 30, 2020

Conditions
Metastatic ER+ Breast Cancer
Interventions
DRUG

TTC-352

Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.

Trial Locations (4)

53792

University of Wisconsin, Carbone Cancer Center, Madison

55101

HealthPartners Institute, Regions Cancer Care Center, Saint Paul

57104

Sanford Health, Sioux Falls

85258

HonorHealth Research Institute, Scottsdale

All Listed Sponsors
lead

TTC Oncology, LLC

INDUSTRY

NCT03201913 - Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy | Biotech Hunter | Biotech Hunter